Regulatory milestones

Cubist Pharmaceuticals Inc. (NASDAQ:CBST) gained $3.69 to $72.24 on Friday after FDA approved an NDA for Cubist's Sivextro tedizolid to treat acute bacterial skin and skin structure infections (ABSSSIs) caused by certain susceptible bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). Sivextro is also under EMA review to treat complicated skin and soft tissue infections (cSSTIs).